My Profile

Search abstracts

Lewis Sheiner


2020
Ljubljana, Slovenia



2019
Stockholm, Sweden

2018
Montreux, Switzerland

2017
Budapest, Hungary

2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
KÝbenhavn, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland



Printable version

PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
ISSN 1871-6032

Reference:
PAGE 23 (2014) Abstr 3218 [www.page-meeting.org/?abstract=3218]


PDF poster/presentation:
Click to open Click to open

Poster: Drug/Disease modeling - Absorption & PBPK


III-25 Margreke Brill Midazolam pharmacokinetics following semi-simultaneous oral and intravenous administration in morbidly obese patients before and 1 year after bariatric surgery

Margreke JE Brill (1,2), Anne van Rongen (1,2), Aletta PI Houwink (3), Bert van Ramshorst (4), Eric J Hazebroek(4), Eric PA van Dongen (3), Catherijne AJ Knibbe (1,2)

(1) Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, The Netherlands. (2) Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands. (3) Department of Anaesthesiology and Intensive Care, St. Antonius Hospital, Nieuwegein, The Netherlands. (4) Department of Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands.

Objectives: Gastric bypass/sleeve surgery is considered the most successful treatment for morbid obesity (body mass index, BMI >40 kg/m2). As both surgery induced weight loss and gastro-intestinal alterations may influence a drugs pharmacokinetics, we aimed to quantify the influence of bariatric surgery on oral and intravenous pharmacokinetics of CYP3A substrate midazolam in patients before and 1 year post bariatric surgery.

Methods: Twenty morbidly obese patients [144.4 kg (112-186 kg)] participated before gastric bypass/sleeve surgery and 18 patients [-44.5 kg (21-58 kg)] returned 52 ± 2 weeks after surgery. On both occasions, patients received 7.5 mg oral and 5 mg i.v. midazolam separated by 160 ± 50 minutes and 21-23 blood samples were collected until 9-11 h post oral dose. Population pharmacokinetic modeling was performed using NONMEM 7.2.

Results: Midazolam concentrations of both groups were best described by a three-compartment model with equalized peripheral volumes and a transit compartment model for absorption with transit rates set equal to the absorption rate. Post bariatric surgery, population mean (RSE%) midazolam absorption rate and clearance were higher compared to before bariatric surgery [0.40 (11%) vs. 0.17 (10%) min-1 (p<0.01) and 0.68 (5%) vs. 0.49 (11%) L/min (p<0.01), respectively] and peripheral volume of distribution was lower [51 (11%) vs. 84 (13%) L (p<0.01)]. Bioavailability and central volume of distribution were similar to before surgery [0.54 (8%) and 51(14%) L, respectively].

Conclusions: Oral and i.v. midazolam pharmacokinetics in post gastric bypass/sleeve patients revealed higher oral absorption rate and clearance compared to before bariatric surgery, while the peripheral volume of distribution was lower and bioavailability was unaltered.